Marshall Wace, LLP Arrowhead Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 59,760 shares of ARWR stock, worth $990,223. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,760
Previous 86,633
31.02%
Holding current value
$990,223
Previous $1.63 Million
53.26%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ARWR
# of Institutions
300Shares Held
98MCall Options Held
306KPut Options Held
432K-
Black Rock Inc. New York, NY15.7MShares$260 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$219 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$184 Million2.29% of portfolio
-
State Street Corp Boston, MA7MShares$116 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$86.7 Million1.32% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.75B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...